Andrei Pikalov, MD, PhD

  • 14Articles
  • 73KReads
  • 2007–2023Active
  • 54Collaborators
  • 3.2KCitations

About

Andrei Pikalov, MD, PhD, is affiliated with Sunovion Pharmaceuticals Inc. in Teaneck, New Jersey, and Marlborough, Massachusetts. He has contributed to 14 articles published between 2007 and 2023 in Psychiatrist.com, covering topics such as depression, schizophrenia, bipolar disorder, movement disorders, neurology, sexual dysfunction, and sleep. Frequent collaborators include Antony Loebel, Josephine Cucchiaro, and Ronald N. Marcus.

Publications

JCP
Lurasidone and Anxiety Symptoms in Bipolar Depression
Original Research

Lurasidone and Anxiety Symptoms in Bipolar Depression

June 7, 2023

Lurasidone was superior to placebo at reducing anxiety in bipolar depression. Change in anxiety symptoms was predicted by sleep disturbance at baseline.
, , , et al
JCP
Original Research

Lurasidone and Sexual Function

August 7, 2018

As you probably know, sexual dysfunction is a common side effect of antidepressants and antipsychotics. This secondary analysis of an RCT examines whether the atypical antipsychotic lurasidone was linked...
, , , et al
JCP
Original Research

Lurasidone in Older Adults With Bipolar Depression

October 26, 2016

Lurasidone's favorable safety profile in younger adults suggests it would be a good candidate for the treatment of episodes of bipolar depression in older adults. For your patients 55...
, , , et al
JCP
Original Research

Lurasidone and Bipolar Depression

April 22, 2015

Read the analysis of a randomized placebo-controlled trial of Lurasidone in the Treatment of Bipolar Depression With Mixed (Subsyndromal Hypomanic) Features.
, , , et al
JCP
Original Research

Effectiveness of Lurasidone for Patients With Schizophrenia Following 6 Weeks of Acute Treatment With Lurasidone, Olanzapine, or Placebo: A 6-Month, Open-Label, Extension Study

March 13, 2013

, , , et al
JCP
Original Research

Effectiveness of Lurasidone in Patients with Schizophrenia or Schizoaffective Disorder Switched From Other Antipsychotics: A Randomized, 6-Week, Open-Label Study

January 15, 2013

, , , et al
JCP
Original Research

Metabolic Syndrome in Patients Enrolled in a Clinical Trial of Aripiprazole in the Maintenance Treatment of Bipolar I Disorder: A Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial

May 4, 2010

, , , et al
PCC
Original Research

Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163)

December 17, 2009

, , , et al
JCP
Original Research

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of Adjunctive Aripiprazole for Schizophrenia or Schizoaffective Disorder Inadequately Treated With Quetiapine or Risperidone Monotherapy

October 15, 2009

, , , et al
JCP
Original Research

Akathisia: An Updated Review Focusing on Second-Generation Antipsychotics

April 21, 2009

, , , et al
JCP
Original Research

Adjunctive Aripiprazole in Major Depressive Disorder: Analysis of Efficacy and Safety in Patients With Anxious and Atypical Features

December 31, 2008

, , , et al
PCC
Original Research

Examining the Efficacy of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Analysis of 2 Studies

December 15, 2008

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe